NetworkNewsBreaks – Revance Therapeutics Inc. (NASDAQ: RVNC) Featured in Mizuho Securities Research Report
Revance Therapeutics Inc. (NASDAQ: RVNC) was featured in a recent equity research report published by Mizuho Securities USA LLC. The report reads, “Revance announced positive results from two phase 2a open-label, dose escalation studies of DAXI for dynamic forehead following glabellar line injections, and lateral canthal lines (crow's feet). We believe the news is incrementally positive for the company, and we reaffirm our Buy rating and $35 price target.” To request access to the full report, visit http://nnw.fm/SaZ9d About Revance Therapeutics Inc. Revance Therapeutics Inc. is a biotechnology company focused on innovative aesthetic and therapeutic offerings, including its next-generation neuromodulator…







